Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment

In this manuscript, we discuss the expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from a clinical and pharmacovigilant point of view. We suggest that though the results of two-phase III double-blind clinical trial...

Descripción completa

Detalles Bibliográficos
Autor principal: Kelleni, Mina T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894610/
https://www.ncbi.nlm.nih.gov/pubmed/33644693
http://dx.doi.org/10.1007/s42399-021-00824-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894610/
https://www.ncbi.nlm.nih.gov/pubmed/33644693
http://dx.doi.org/10.1007/s42399-021-00824-4

Ejemplares similares